An Early Access Programme for Moxetumomab Pasudotox in Relapsed/Refractory Hairy Cell Leukemia

NCT03501615 · clinicaltrials.gov ↗

APPROVED_FOR_MARKETING

Status

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Hairy Cell Leukemia

Interventions

DRUG: Moxetumomab Pasudotox

Sponsor

AstraZeneca